Skip to main content
. Author manuscript; available in PMC: 2025 Mar 1.
Published in final edited form as: Am J Cardiol. 2024 Jan 7;214:59–65. doi: 10.1016/j.amjcard.2023.12.052

Figure 2.

Figure 2.

Cumulative incidence of adverse events in patients without CTO and nonrevascularized CTO. Unadjusted cumulative incidence function was used to visualize differences in survival outcomes in patients with CTO who did not receive CTO revascularization (n = 668) and significant CAD without CTO (n = 2,675), coupled with log-rank tests. Nonrevascularized CTO was associated with higher event rates of all-cause mortality, cardiovascular death, and a MACE, defined as cardiovascular death/MI/HF hospitalization. The no-CTO group had significant CAD, defined as ≥50% stenosis in ≥1 coronary artery. Revascularization was defined as percutaneous intervention or CABG that bypassed the CTO.